The new drug commentary on ertugliflozin has been corrected. View corrected article.

The paragraph on lower limb amputations cited incorrect figures. The original text “Lower limb amputations were more common in people receiving ertugliflozin (0.47% with 5 mg dose, 0.26% with 15 mg dose) than those who did not receive it (0.07%). This has previously been found with canagliflozin which is no longer registered for use in Australia.” has been replaced with “Lower limb amputations were more common in people receiving the higher ertugliflozin dose (0.47% with 15 mg dose) than those who received the lower dose (0.06% with 5 mg dose) or the comparator (0.07%). Lower limb amputations have previously been found with canagliflozin which is no longer registered for use in Australia.”